U.S. Professional Services Stock News

Enova International's FY 2025 Earnings Snapshot Enova International (ENVA) has capped FY 2025 with fourth quarter revenue of US$412.9 million and basic EPS of US$3.19, while trailing twelve month EPS sits at US$12.25 on revenue of about US$1.5 billion. The company has seen quarterly revenue move from US$323.5 million in Q3 2024 to US$412.9 million in Q4 2025, with basic EPS over that stretch ranging from US$1.64 to just above US$3 per share. With net margin at 20.7% over the last year versus...

Starbucks (SBUX) opened fiscal Q1 2026 with revenue of US$9.9b and basic EPS of US$0.26, alongside net income of US$293.3m, setting the tone for how investors assess the latest quarter against a year of softer profitability. Over the past year, the company has seen quarterly revenue range from US$8.8b to US$9.6b and EPS move between US$0.12 and US$0.69, while trailing twelve month figures sit at US$37.7b of revenue, EPS of US$1.20 and net income of US$1.37b. With the trailing net margin at 5%...

John Marshall Bancorp (JMSB) just turned in another steady quarter for FY 2025, with Q3 revenue of about US$15.9 million and basic EPS of roughly US$0.38 on net income of US$5.4 million. The bank has seen revenue move from US$13.4 million and EPS of about US$0.30 in Q3 2024 to US$15.9 million and EPS of roughly US$0.38 in Q3 2025. Trailing 12 month EPS sits around US$1.41 on net income of about US$20.0 million, which highlights a story where higher earnings and firmer profitability metrics...

Taysha Gene Therapies recently reported progress in its TSHA-102 gene therapy program for Rett syndrome, including dosing the first patient in the pivotal REVEAL trial and securing FDA alignment on the study design, while senior executives disclosed significant insider stock sales. This combination of clinical and regulatory milestones with insider activity offers a rare window into both the program’s momentum and leadership’s capital decisions. We’ll now examine how the FDA’s alignment on...

NVR (NVR) has just posted its FY 2025 third quarter numbers, with revenue of US$2.6b and basic EPS of US$119.26, set against a trailing 12 month EPS of US$484.98 and revenue of US$10.6b. Over recent quarters, revenue has moved from US$2.6b in Q2 2025 and US$2.4b in Q1 2025, alongside basic EPS of US$114.52 and US$100.41 respectively. This gives investors a clear read on the run rate as they weigh the latest figures against a net profit margin that has eased from 15.9% to 13.5% over the past...

Orrstown Financial Services (ORRF) has rounded out FY 2025 with fourth quarter revenue of US$64.8 million and basic EPS of US$1.12, alongside trailing twelve month revenue of US$252.1 million and EPS of US$4.21. Over the last few quarters, revenue has moved from US$60.1 million in Q4 2024 to US$64.8 million in Q4 2025, while quarterly basic EPS has shifted from US$0.72 to US$1.12 over the same period. This frames a year in which trailing net income reached US$80.9 million. With a trailing net...

German American Bancorp (GABC) just posted its FY 2025 fourth quarter numbers, reporting revenue of US$94.0 million and EPS of US$0.95, supported by quarterly net income of US$35.7 million. The bank’s revenue moved from US$64.5 million in Q4 2024 to US$94.0 million in Q4 2025, while quarterly EPS increased from US$0.78 to US$0.95 over the same period, indicating a notably different earnings profile than a year ago. With a trailing 12 month net profit margin of 32% and a P/E above sector...

Brinker International (EAT) just posted Q2 2026 results with revenue of US$1.35 billion and basic EPS of US$2.23, alongside net income of US$99.5 million, setting the tone for how its restaurant footprint and sales trends are feeding into profitability. The company has seen quarterly revenue move from US$1.36 billion in Q2 2025 to US$1.43 billion in Q3 2025 and US$1.46 billion in Q4 2025, while basic EPS over that stretch ran from US$2.67 in Q2 2025 to US$2.68 in Q3 2025 and US$2.40 in Q4...

Teva Pharmaceutical Industries (NYSE:TEVA) has just posted its FY 2025 third quarter numbers, with revenue of US$4.5b and basic EPS of US$0.38, as the trailing 12 month line shows revenue of US$16.8b and basic EPS of US$0.62. Over recent quarters the company has seen revenue range from US$4.2b in Q4 2024 to US$4.5b in Q3 2025, while basic EPS moved from a loss of US$0.19 in Q4 2024 to a profit of US$0.38 in Q3 2025. This sets up a story where margin trends and the mix of products in late...

Polaris (PII) closed out FY 2025 with Q4 revenue of US$1.9b and a basic EPS loss of US$5.34, as net income excluding extra items came in at a loss of US$303.6m. Over recent quarters the company has seen revenue move from US$1.6b in Q1 2025 to US$1.9b in Q4 2025. Basic EPS shifted from a loss of US$1.17 in Q1 to a larger loss of US$5.34 in Q4, with trailing twelve month EPS at a loss of US$8.18 on US$7.2b of revenue. For investors, the headline takeaway is that top line scale sits against...

UP Fintech Holding recently drew increased attention as analysts raised earnings estimates and assigned it a favorable ranking based on those revised expectations. At the same time, options markets showed an unusually strong tilt toward calls and higher implied volatility, underscoring intensified positioning ahead of the company’s March earnings release, which has now passed. We’ll now examine how this surge in bullish options activity shapes UP Fintech Holding’s investment narrative for...

Lakeland Financial (LKFN) closed out FY 2025 with fourth quarter revenue of US$69.8 million and basic EPS of US$1.17, alongside trailing twelve month EPS of US$4.02. Over the past year, total revenue has moved from US$236.8 million on a trailing basis at the end of 2024 to US$257.2 million by the fourth quarter of 2025, while quarterly EPS shifted from US$0.94 in Q4 2024 to US$1.17 in Q4 2025. This gives investors a clear view of how the income line is tracking into the new year. With a...

Why Waters (WAT) is on investors’ radar today Waters (WAT) has been drawing attention after recent share price moves, with the stock roughly flat over the past month but showing a gain over the past 3 months and mixed longer term returns. See our latest analysis for Waters. Recent trading has cooled slightly, with a 7 day share price return of 2.94% and a 1 day move of a 1.30% decline. However, the 90 day share price return of 12.29% contrasts with a 1 year total shareholder return of a 4.74%...

If you are wondering whether Soleno Therapeutics' current share price reflects its true worth, this article walks through what the numbers can and cannot tell you about value. The stock closed at US$41.61, with recent returns showing a 4.5% decline over 7 days, a 12.5% decline over 30 days and an 11.8% decline year to date. Its 3-year return is very large. Recent coverage of Soleno has focused on its position in pharmaceuticals and biotech, as investors weigh how its pipeline and clinical...

Zydus Lifesciences is reported to be exploring the acquisition of a majority stake in Ardelyx (NasdaqGM:ARDX). Ardelyx has initiated a Phase 3 clinical trial of IBSRELA in chronic idiopathic constipation, aiming to expand the drug's use beyond its current indication. These developments come as Ardelyx trades at $7.89, with recent share price moves attracting fresh investor attention. For investors watching Ardelyx, the combination of M&A interest and pipeline progress makes this an active...

Northrop Grumman (NOC) closed FY 2025 with fourth quarter revenue of US$11.7b and basic EPS of US$9.99, alongside net income of US$1,427m, setting a clear marker for how the year wrapped up operationally. Over recent periods, quarterly revenue has ranged from US$9.5b to US$11.7b while EPS has moved between US$3.33 and US$9.99. This gives investors a solid run of data points to judge consistency and the latest step up in earnings power. With trailing twelve month EPS of US$29.14 and a net...

If you are wondering whether Coastal Financial at US$104.58 is still fairly priced or starting to look stretched, you are not alone. This article is here to help you frame that question clearly. The stock has pulled back recently, with a 4.7% decline over 7 days, a 10.5% decline over 30 days and a 7.7% decline year to date, after a 21.1% return over the past year and a very large gain over 5 years. Recent attention on Coastal Financial has focused on its role within the US regional banking...

If you are wondering whether GCM Grosvenor at around US$11.37 is priced attractively or not, this article walks through what the current share price might be implying about value. The stock is roughly flat year to date with a 0.6% return, after a 12.9% decline over the last 12 months and a 45.5% gain across the past 3 years, so recent moves may look very different depending on your holding period. Recent attention on alternative asset managers and listed managers in general has kept GCM...

Nucor (NUE) just closed out FY 2025 with fourth quarter revenue of US$7.7 billion and basic EPS of US$1.67, alongside net income of US$383 million, setting the tone for how investors read its latest steel cycle update. Over the past two reported fourth quarters, revenue has moved from US$7.1 billion in FY 2024 to US$7.7 billion in FY 2025, while basic EPS shifted from US$1.22 to US$1.67. This gives a clear view of how the top line and per share earnings have tracked through the year. With...

Chime Financial, NasdaqGS:CHYM, has been named the Official Banking and Credit Partner of the Portland Fire. The agreement includes front of jersey branding, exclusive member experiences, VIP access, and community-focused programs for fans in Portland. The partnership also features local content series and charitable initiatives aimed at deepening ties with the Portland community. For investors watching Chime Financial, NasdaqGS:CHYM, this Portland Fire partnership ties a consumer-facing...

If you are wondering whether LendingClub's share price still offers value, the recent trading history gives you a clear starting point to assess what you might be paying for each dollar of fundamentals. The stock most recently closed at US$20.81, with returns of 4.5% over the last 7 days, 6.0% over 30 days, 8.8% year to date, 23.6% over 1 year, 114.8% over 3 years and 80.8% over 5 years. This frames the question of whether the current price fully reflects these moves. Recent coverage has...

If you are wondering whether Casella Waste Systems is reasonably priced at around US$105.82, this article will walk through what that number could mean for you as an investor. The stock has seen mixed returns, with a 2.0% gain over the last 7 days, 4.6% over the past month, 7.3% year to date, but a small 0.6% decline over the past year. The 3 year and 5 year returns sit at 32.1% and 82.4% respectively. Recent attention on Casella Waste Systems has largely come from its role as a listed US...

If you are wondering whether Intellia Therapeutics at around US$14.83 is a bargain or a value trap, you are not alone. The stock has returned 15.6% over the last 7 days, 57.1% over the past month, 61.0% year to date, yet longer term holders have seen a 48.2% 1 year return alongside 65.1% and 79.0% declines over 3 and 5 years respectively. These sharp swings have come as Intellia Therapeutics stays in focus as a gene editing company in the biotech space. In this area, sentiment can shift...

Sanmina (SANM) has kicked off Q1 2026 with revenue of about US$3.2b and basic EPS of US$0.91, setting the tone for how its earnings story is shaping up this year. The company has seen quarterly revenue move from US$2,006.3m in Q1 2025 to US$3,189.7m in Q1 2026, while basic EPS shifted from US$1.20 to US$0.91 over the same period. Trailing 12 month EPS now sits at US$4.27 on revenue of US$9.3b. With trailing net margins thinner than last year and a large one off loss still in the rear-view...